Table of Contents
OVERVIEW
EXECUTIVE SUMMARY
- Strategic scoping and focus
- Datamonitor insight into the prostate cancer market
- Contributing experts
- Related reports
- Upcoming reports
1. PIPELINE OVERVIEW AND DYNAMICS
- Key findings
- Pipeline overview
- Pipeline summary
- Comparative forecasts
- Datamonitor pipeline assessment summary
- Key companies involved in the prostate cancer pipeline
- Sanofi-Aventis
- AstraZeneca
- Novartis
- Key R&D company strategies
- The castration-resistant prostate cancer population holds the most
commercial potential
- The inclusion of molecular targeted therapies into prostate cancer
treatment appears to be the way forward
2. PROSTATE CANCER - MARKET POTENTIAL
- Key findings
- Definition
- Introduction
- Histology
- Risk factors
- Symptoms
- Screening and diagnosis
- Patient segmentation
- Prostate cancer is staged using the TNM system and a
histologically-based Gleason score
- Further segmentation dictates subsequent treatment options
- Epidemiology
- Seven major markets
- Rest of the world
- Current treatment options
- Antihormonal therapy
- Cytotoxic therapy
- Current comparator therapy
- Taxotere (docetaxel; Sanofi-Aventis)
- Unmet need in prostate cancer
- More second-line therapy options are needed for metastatic
castration-resistant prostate cancer
- Less toxic therapy options are needed for first-line metastatic
castration-resistant prostate cancer
- Side effects from antihormonal therapies may affect compliance
- Greater R&D interest in terms of targeted therapies
- Target product profile versus current level of attainment
3. R&D APPROACH
- Key findings
- Clinical trial design in prostate cancer
- Patient selection
- Clinical trial duration
- The advent of novel therapies
- Clinical trial endpoints in prostate cancer
4. PIPELINE ANALYSIS & FORECASTS: MOLECULAR TARGETED THERAPIES
- Key findings
- Overview of the molecular targeted therapies
- Pipeline summary
- Comparative forecasts
- Abiraterone (CB-7630; Cougar Biotechnology/BTG/Johnson & Johnson)
- Drug overview
- Drug profile
- Key historical events
- SWOT analysis
- Clinical trial data
- Clinical attractiveness
- Commercial attractiveness
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Forecasts to 2018
- Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis)
- Drug overview
- Drug profile
- Key historical events
- SWOT analysis
- Clinical trial data
- Clinical attractiveness
- Commercial attractiveness
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Forecasts to 2018
- Avastin (bevacizumab; Genentech/Roche/Chugai)
- Drug overview
- Drug profile
- Key historical events
- SWOT analysis
- Clinical trial data
- Clinical attractiveness
- Commercial attractiveness
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Forecasts to 2018
- Sprycel (dasatinib; Bristol-Myers Squibb)
- Drug overview
- Drug profile
- Key historical events
- SWOT analysis
- Clinical trial data
- Clinical attractiveness
- Commercial attractiveness
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Forecasts to 2018
- Sutent (sunitinib; Pfizer)
- Drug overview
- Drug profile
- Key historical events
- SWOT analysis
- Clinical trial data
- Clinical attractiveness
- Commercial attractiveness
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Forecasts to 2018
- Zibotentan (ZD-4054; AstraZeneca)
- Drug overview
- Drug profile
- Key historical events
- SWOT analysis
- Clinical trial data
- Clinical attractiveness
- Commercial attractiveness
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Forecasts to 2018
5. PIPELINE ANALYSIS & FORECASTS: CYTOTOXIC THERAPIES
- Key findings
- Overview of the cytotoxic therapies
- Pipeline summary
- Comparative forecasts
- Cabazitaxel (XRP-6258; Sanofi-Aventis)
- Drug overview
- Drug profile
- Key historical events
- SWOT analysis
- Clinical trial data
- Clinical attractiveness
- Commercial attractiveness
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Forecasts to 2018
6. PIPELINE ANALYSIS & FORECASTS: IMMUNOTHERAPIES
- Key findings
- Overview of the immunotherapies
- Pipeline summary
- Comparative forecasts
- Ipilimumab (MDX-010; Medarex/Bristol-Myers Squibb)
- Drug overview
- Drug profile
- Key historical events
- SWOT analysis
- Clinical trial data
- Clinical attractiveness
- Commercial attractiveness
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Forecasts to 2018
- Provenge (sipuleucel-T; Dendreon)
- Drug overview
- Drug profile
- Key historical events
- SWOT analysis
- Clinical trial data
- Clinical attractiveness
- Commercial attractiveness
- Datamonitor drug assessment summary
- Satisfaction of unmet needs
- Forecasts to 2018
7. INNOVATIVE EARLY-STAGE APPROACHES
- Key findings
- Overview of early-stage innovative projects
- Epidermal growth factor receptor
- Prostate-specific membrane antigen
- Akt
- The future of treatment in prostate cancer
- Greater understanding of cancer evolution should result in a large range
of potential drug targets
- Longer term control of tumors with reduced toxicity is crucial
- Improvements in diagnostics and prognostic analysis will enhance
cost-effectiveness of treatment
- Enhanced preventative strategies will ease the disease burden
BIBLIOGRAPHY
APPENDIX
- Methodology
- Epidemiology forecasts
- Product forecasts
- Datamonitor drug assessment scorecard
TABLES
- Table: Late-phase pipeline products in development for prostate cancer,
2009
- Table: Sales forecasts for late-phase prostate cancer pipeline products in
the seven major markets, 2009 - 2018 ($m)
- Table: Sanofi-Aventis marketed and pipeline oncology portfolio, 2009
- Table: AstraZeneca marketed and pipeline oncology portfolio, 2009
- Table: Novartis marketed and pipeline oncology portfolio, 2009
- Table: Incidence rates of prostate cancer per 100,000 population in the US
by race, 2000 - 04
- Table: Crude incidence rates of prostate cancer per 100,000 population in
the seven major pharmaceutical markets, 2002
- Table: Estimated incidence of prostate cancer in the seven major
pharmaceutical markets, 2002 - 2018
- Table: Approved antihormonal therapies for prostate cancer, 2009
- Table: Approved cytotoxic therapies for prostate cancer, 2009
- Table: Taxotere (docetaxel) - drug profile, 2009
- Table: Ability of Taxotere to meet unmet needs in prostate cancer, 2009
- Table: Targeted therapy subgroup mechanisms of action
- Table: Late-phase molecular targeted therapies in development for prostate
cancer, 2009
- Table: Forecast assumptions for molecular targeted therapy prostate cancer
pipeline products across the seven major markets, 2009 (1 of 2)
- Table: Forecast assumptions for molecular targeted therapy prostate cancer
pipeline products across the seven major markets, 2009 (2 of 2)
- Table: Sales forecasts for molecular targeted therapy prostate cancer
pipeline products in the seven major markets, 2009 - 2018 ($m)
- Table: Abiraterone - drug profile, 2009
- Table: Abiraterone: key historical events
- Table: Clinical development of abiraterone in prostate cancer, 2009
- Table: Ability of abiraterone to meet unmet needs in prostate cancer, 2009
- Table: Sales forecast for abiraterone in prostate cancer across the seven
major markets, 2009 - 2018 ($m)
- Table: Aflibercept - drug profile, 2009
- Table: Aflibercept: key historical events
- Table: Clinical development of aflibercept in prostate cancer, 2009
- Table: Ability of aflibercept to meet unmet needs in prostate cancer, 2009
- Table: Sales forecast for aflibercept in prostate cancer across the seven
major markets, 2009 - 2018 ($m)
- Table: Avastin - drug profile, 2009
- Table: Avastin: key historical events
- Table: Clinical development of Avastin in prostate cancer, 2009
- Table: Ability of Avastin to meet unmet needs in prostate cancer, 2009
- Table: Sales forecast for Avastin in prostate cancer across the seven
major markets, 2009 - 2018 ($m)
- Table: Sprycel - drug profile, 2009
- Table: Sprycel: key historical events
- Table: Clinical development of Sprycel in prostate cancer, 2009
- Table: Ability of Sprycel to meet unmet needs in prostate cancer, 2009
- Table: Sales forecast for Sprycel in prostate cancer across the seven
major markets, 2009 - 2018 ($m)
- Table: Sutent - drug profile, 2009
- Table: Sutent: key historical events
- Table: Clinical development of Sutent in prostate cancer, 2009
- Table: Ability of Sutent to meet unmet needs in prostate cancer, 2009
- Table: Sales forecast for Sutent in prostate cancer across the seven major
markets, 2009 - 2018 ($m)
- Table: Zibotentan - drug profile, 2009
- Table: Zibotentan: key historical events
- Table: Clinical development of zibotentan in prostate cancer, 2009
- Table: Ability of zibotentan to meet unmet needs in prostate cancer, 2009
- Table: Sales forecast for molecular targeted therapy prostate cancer
pipeline products in the seven major markets, 2009 - 2018 ($m)
- Table: Cytotoxic therapy subgroup mechanisms of action
- Table: Late-phase cytotoxic therapy in development for prostate cancer,
2009
- Table: Forecast assumptions for cytotoxic therapy prostate cancer pipeline
product across the seven major markets, 2009
- Table: Sales forecasts for cytotoxic therapy prostate cancer pipeline
product in the seven major markets, 2009 - 2018 ($m)
- Table: Cabazitaxel - drug profile, 2009
- Table: Cabazitaxel: key historical events
- Table: Clinical development of cabazitaxel in prostate cancer, 2009
- Table: Ability of cabazitaxel to meet unmet needs in prostate cancer, 2009
- Table: Sales forecast for cabazitaxel in prostate across the seven major
markets, 2009 - 2018 ($m)
- Table: Immunotherapy subgroup mechanisms of action
- Table: Late-phase immunotherapies in development for prostate cancer, 2009
- Table: Forecast assumptions for immunotherapy prostate cancer pipeline
products across the seven major markets, 2009
- Table: Sales forecasts for immunotherapy prostate cancer pipeline products
in the seven major markets, 2009 - 2018 ($m)
- Table: Ipilimumab - drug profile, 2009
- Table: Ipilimumab: key historical events
- Table: Clinical development of ipilimumab in prostate cancer, 2009
- Table: Ability of ipilimumab to meet unmet needs in prostate cancer, 2009
- Table: Sales forecast for ipilimumab in prostate cancer across the seven
major markets, 2009 - 2018 ($m)
- Table: Provenge - drug profile, 2009
- Table: Provenge: key historical events
- Table: Clinical development of Provenge in prostate cancer, 2009
- Table: Ability of Provenge to meet unmet needs in prostate cancer, 2009
- Table: Sales forecast for Provenge in prostate cancer across the seven
major markets, 2009 - 2018 ($m)
- Table: Top 10 early-stage prostate cancer drug targets, 2009
- Table: Datamonitor drug assessment parameters
FIGURES
- Figure: Prostate cancer pipeline split by development phase and drug
class, 2009
- Figure: Datamonitor drug assessment summary for late-phase pipeline
products in development for prostate cancer, 2009
- Figure: Incidence and mortality from prostate cancer in 2009 and 2018
across the seven major pharmaceutical markets
- Figure: Top 5 rest of world countries with highest incidence of prostate
cancer, 2009 - 2018
- Figure: Key unmet needs in prostate cancer, 2009
- Figure: Datamonitor drug assessment summary for molecular targeted
therapies in development for prostate cancer, 2009
- Figure: Abiraterone SWOT analysis, 2009
- Figure: Phase II COU-AA-002 results for first -line abiraterone plus
prednisone in castration-resistant prostate cancer
- Figure: Phase II COU-AA-003 results for second -line abiraterone in
castration-resistant prostate cancer
- Figure: Phase II COU-AA-004 results for second/third-line abiraterone and
prednisone in metastatic castration-resistant prostate cancer
- Figure: Datamonitor drug assessment summary for abiraterone in prostate
cancer, 2009
- Figure: Aflibercept SWOT analysis, 2009
- Figure: Datamonitor drug assessment summary for aflibercept in prostate
cancer, 2009
- Figure: Avastin SWOT analysis, 2009
- Figure: Initial Phase II results investigating first-line Avastin,
Taxotere and estramustine in metastatic castration-resistant prostate cancer
- Figure: Phase II results investigating first-line Avastin, Taxotere and
Thalomid in metastatic castration-resistant prostate cancer
- Figure: Phase II results investigating neoadjuvant Taxotere and Avastin in
high-risk localized prostate cancer
- Figure: Datamonitor drug assessment summary for Avastin in prostate
cancer, 2009
- Figure: Sprycel SWOT analysis, 2009
- Figure: Phase I/II results investigating first/second-line Sprycel and
Taxotere metastatic castration-resistant prostate cancer
- Figure: Phase II results investigating first-line Sprycel in progressive
metastatic castration-resistant prostate cancer
- Figure: Datamonitor drug assessment summary for Sprycel in prostate
cancer, 2009
- Figure: Sutent SWOT analysis, 2009
- Figure: Phase II results investigating first-line Sutent, Taxotere and
prednisone in metastatic castration-resistant prostate cancer
- Figure: Phase II results investigating second/third-line Sutent in
progressive metastatic castration-resistant prostate cancer following failure
of Taxotere-based chemotherapy
- Figure: Phase II results investigating neoadjuvant Sutent plus androgen
deprivation therapy in high-risk localized prostate cancer prior to radical
prostatectomy
- Figure: Datamonitor drug assessment summary for Sutent in prostate cancer,
2009
- Figure: Zibotentan SWOT analysis, 2009
- Figure: Phase II study investigating first-line zibotentan in
castration-resistant prostate cancer with bone metastases
- Figure: Datamonitor drug assessment summary for zibotentan in prostate
cancer, 2009
- Figure: Datamonitor drug assessment summary for cytotoxic therapies in
development for prostate cancer, 2009
- Figure: Cabazitaxel SWOT analysis, 2009
- Figure: Datamonitor drug assessment summary for cabazitaxel in prostate
cancer, 2009
- Figure: Datamonitor drug assessment summary for immunotherapies in
development for prostate cancer, 2009
- Figure: Ipilimumab SWOT analysis, 2009
- Figure: Phase I/II study investigating first/second-line ipilimumab alone
and in combination with radiotherapy in metastatic castration-resistant
prostate cancer
- Figure: Datamonitor drug assessment summary for ipilimumab in prostate
cancer, 2009
- Figure: Provenge SWOT analysis, 2009
- Figure: Phase III D9901 results investigating Provenge in asymptomatic
metastatic castration-resistant prostate cancer
- Figure: Phase III IMPACT results investigating Provenge in asymptomatic or
mildly symptomatic metastatic castration-resistant prostate cancer
- Figure: Analysis of patient subgroup from Phase III D9901 and D9902A
studies who received Taxotere following Provenge or placebo
- Figure: Preliminary Phase III PROTECT results investigating Provenge in
hormone-sensitive non-metastatic prostate cancer
- Figure: Datamonitor drug assessment summary for Provenge in prostate
cancer, 2009
- Figure: Early-stage prostate cancer pipeline split by drug class, 2009
- Figure: Datamonitor drug assessment summary for molecular targeted
therapies in development for prostate cancer, 2009
|
Related Report
|
View Cart
